Form | Jotup

LUNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Luna Innovations Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Tuesday, April 9, 2024

8-K, Committee, Form, News, Luna Innovations, LUNA, Bank statement, Complaint, Retirement, Court, Person, Cryptocurrency

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Luna Innovations Incorporated (“Luna Innovations” or “the Company”) (NASDAQ: LUNA) and certain of its officers.

Key Points:

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Luna Innovations Incorporated (“Luna Innovations” or “the Company”) (NASDAQ: LUNA) and certain of its officers.
According to the Complaint, Luna Innovations is a technology company that is focused on fiber optics.
If you suffered a loss in Luna Innovations you have until May 31, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Longeveron Announces Pricing of $5.25 Million Public Offering

Retrieved on:

Monday, April 8, 2024

3rd Floor, Form, Hypoplastic left heart syndrome, Sale, Public expenditure, Security (finance), HLHS, Prospectus

The closing of the offering is expected to occur on or about April 10, 2024, subject to the satisfaction of customary closing conditions.

Key Points:

The closing of the offering is expected to occur on or about April 10, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds to the Company from the offering are expected to be approximately $5.25 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
The offering is being made only by means of a prospectus, which forms a part of the effective registration statement.
A preliminary prospectus relating to the public offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov .

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in HireRight Holdings Corporation of Class Action Lawsuit and Upcoming Deadlines – HRT

Retrieved on:

Monday, April 8, 2024

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.

Key Points:

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.
To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on:

Monday, April 8, 2024

Prior, Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points:

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Renalytix Announces Financing with Expected Size of up to $4 Million

Retrieved on:

Monday, April 8, 2024

Common stock, Form, Sale, ADS, Prospectus, Fundraising, Security (finance)

Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share).

Key Points:

Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share).
The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing.
The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced.
The completion of the sale and purchase of the Initial Tranche Shares is expected take place no later than 11 April 2024, subject to customary closing conditions.

Sonder Holdings Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Retrieved on:

Friday, April 5, 2024

Failure, Letter, Notice, Form, SAN, Security (finance), Annual report, Calendar, Cryptocurrency

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- Sonder Holdings Inc. (NASDAQ: SOND, “Sonder” or the “Company”) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 2, 2024 (the "Notice").

Key Points:

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- Sonder Holdings Inc. (NASDAQ: SOND, “Sonder” or the “Company”) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 2, 2024 (the "Notice").
The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC.
The Company intends to submit a compliance plan to Nasdaq and take the necessary steps to regain compliance with Nasdaq’s listing rules as soon as practicable.
As previously disclosed, the filing of the 2023 Form 10-K was delayed due to the matters described in the Form 12b-25 and the Company’s Current Report on Form 8-K filed with the SEC on March 15, 2024.

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

Retrieved on:

Friday, April 5, 2024

Dietrich Stephan, Rule, Notice, Form, Risk, Annual report, Therapy, Calendar, Cryptocurrency

This Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.

Key Points:

This Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market.
Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until June 3, 2024, to submit a plan to regain compliance with the Rule.
These forward-looking statements include, without limitation, statements relating to our continued listing on Nasdaq and any exception that may be granted by Nasdaq.
Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Ventyx, and Anavex and Encourages Investors to Contact the Firm

Retrieved on:

Friday, April 5, 2024

In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).

Key Points:

In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
USBTC held a 50% interest in a joint venture bitcoin mining facility, located in King Mountain, Texas (the “King Mountain JV”), which was acquired in the Merger.
In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
For more information on the Anavex class action go to: https://bespc.com/cases/AVXL

HRT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that HireRight Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on:

Thursday, April 4, 2024

Employment, Organization, Risk management, Hold, Form, Risk, News, IPO, Alpha, Prospectus, Complaint, Publication, HRT, Court, Register, Person, Security (finance)

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or “the Company”) (NYSE: HRT) and certain of its officers.

Key Points:

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or “the Company”) (NYSE: HRT) and certain of its officers.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in HireRight you have until June 3, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on:

Thursday, April 4, 2024

3rd Floor, Form, SAN, Research, Sale, Public expenditure, Security (finance), Genomics

The closing of the offering is expected to occur on or about April 8, 2024, subject to the satisfaction of customary closing conditions.

Key Points:

The closing of the offering is expected to occur on or about April 8, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (File No.
The offering of such securities in the registered direct offering is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement.